StockData
Whitehawk Therapeutics, Inc. logo

Whitehawk Therapeutics, Inc. (WHWK) stock

WHWKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.08+0.07 (+2.33%)

Close on Nov 17, 2026Market cap $175.59MP/E –Yield –

Whitehawk Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Whitehawk Therapeutics's ebitda for the twelve months ending Mar 31, 2024 was -$74.44M. For fiscal 2025 it was -$114.32M. The highest annual figure on record is -$2.54M in fiscal 2020.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$114.32M–
FY2024Dec 31, 2024-$67.27M–
FY2023Dec 31, 2023-$71.76M–
FY2022Dec 31, 2022-$62.52M–
FY2021Dec 31, 2021-$111.11M–
FY2020Dec 31, 2020-$2.54M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2024Mar 31, 2024-$19.46M–
Q4 FY2023Dec 31, 2023-$17.67M–
Q3 FY2023Sep 30, 2023-$17.81M–
Q2 FY2023Jun 30, 2023-$19.50M–
Q1 FY2023Mar 31, 2023-$16.79M–
Q4 FY2022Dec 31, 2022-$15.43M–
Q3 FY2022Sep 30, 2022-$15.02M–
Q2 FY2022Jun 30, 2022-$18.33M–
Q1 FY2022Mar 31, 2022-$13.74M–
Q4 FY2021Dec 31, 2021-$15.87M-288.8%
Q3 FY2021Sep 30, 2021-$87.28M–
Q2 FY2021Jun 30, 2021-$3.87M–
Q1 FY2021Mar 31, 2021-$4.09M–
Q4 FY2020Dec 31, 2020$8.41M–

More Whitehawk Therapeutics figures

See a number that looks wrong?